EP1740219A4 - Dispositif medical comprenant un revetement permettant de capturer des cellules genetiquement modifiees et ses procedes d'utilisation - Google Patents

Dispositif medical comprenant un revetement permettant de capturer des cellules genetiquement modifiees et ses procedes d'utilisation

Info

Publication number
EP1740219A4
EP1740219A4 EP05745773A EP05745773A EP1740219A4 EP 1740219 A4 EP1740219 A4 EP 1740219A4 EP 05745773 A EP05745773 A EP 05745773A EP 05745773 A EP05745773 A EP 05745773A EP 1740219 A4 EP1740219 A4 EP 1740219A4
Authority
EP
European Patent Office
Prior art keywords
coating
methods
same
medical device
altered cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP05745773A
Other languages
German (de)
English (en)
Other versions
EP1740219B1 (fr
EP1740219A2 (fr
Inventor
Michael John Bradley Kutryk
Robert J Cottone Jr
Stephen M Rowland
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orbus Medical Technologies Inc
Original Assignee
Orbus Medical Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/835,767 external-priority patent/US9522217B2/en
Application filed by Orbus Medical Technologies Inc filed Critical Orbus Medical Technologies Inc
Priority to EP15157258.3A priority Critical patent/EP2946666B1/fr
Publication of EP1740219A2 publication Critical patent/EP1740219A2/fr
Publication of EP1740219A4 publication Critical patent/EP1740219A4/fr
Application granted granted Critical
Publication of EP1740219B1 publication Critical patent/EP1740219B1/fr
Not-in-force legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6957—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a device or a kit, e.g. stents or microdevices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/28—Materials for coating prostheses
    • A61L27/30—Inorganic materials
    • A61L27/303—Carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/28—Materials for coating prostheses
    • A61L27/34—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A61L27/3808—Endothelial cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/08—Materials for coatings
    • A61L29/085—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/08—Materials for coatings
    • A61L29/10—Inorganic materials
    • A61L29/103—Carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
    • A61L29/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08—Materials for coatings
    • A61L31/082—Inorganic materials
    • A61L31/084—Carbon; Graphite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08—Materials for coatings
    • A61L31/10—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • C12N5/0692—Stem cells; Progenitor cells; Precursor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/258—Genetic materials, DNA, RNA, genes, vectors, e.g. plasmids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/64—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Surgery (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Botany (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Materials For Medical Uses (AREA)
EP05745773.1A 2004-04-30 2005-04-29 Dispositif medical comprenant un revetement permettant de capturer des cellules genetiquement modifiees et ses procedes d'utilisation Not-in-force EP1740219B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP15157258.3A EP2946666B1 (fr) 2004-04-30 2005-04-29 Dispositif médical avec revêtement permettant de capturer des cellules génétiquement modifiées et procédés d'utilisation de celui-ci

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56682904P 2004-04-30 2004-04-30
US10/835,767 US9522217B2 (en) 2000-03-15 2004-04-30 Medical device with coating for capturing genetically-altered cells and methods for using same
PCT/US2005/015555 WO2005107817A2 (fr) 2004-04-30 2005-04-29 Dispositif medical comprenant un revetement permettant de capturer des cellules genetiquement modifiees et ses procedes d'utilisation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP15157258.3A Division EP2946666B1 (fr) 2004-04-30 2005-04-29 Dispositif médical avec revêtement permettant de capturer des cellules génétiquement modifiées et procédés d'utilisation de celui-ci

Publications (3)

Publication Number Publication Date
EP1740219A2 EP1740219A2 (fr) 2007-01-10
EP1740219A4 true EP1740219A4 (fr) 2009-01-28
EP1740219B1 EP1740219B1 (fr) 2015-03-04

Family

ID=35320744

Family Applications (2)

Application Number Title Priority Date Filing Date
EP05745773.1A Not-in-force EP1740219B1 (fr) 2004-04-30 2005-04-29 Dispositif medical comprenant un revetement permettant de capturer des cellules genetiquement modifiees et ses procedes d'utilisation
EP15157258.3A Not-in-force EP2946666B1 (fr) 2004-04-30 2005-04-29 Dispositif médical avec revêtement permettant de capturer des cellules génétiquement modifiées et procédés d'utilisation de celui-ci

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP15157258.3A Not-in-force EP2946666B1 (fr) 2004-04-30 2005-04-29 Dispositif médical avec revêtement permettant de capturer des cellules génétiquement modifiées et procédés d'utilisation de celui-ci

Country Status (7)

Country Link
US (1) US9364565B2 (fr)
EP (2) EP1740219B1 (fr)
JP (1) JP2007535389A (fr)
KR (1) KR20070008714A (fr)
CA (1) CA2563329C (fr)
TW (1) TW200605910A (fr)
WO (1) WO2005107817A2 (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7220276B1 (en) * 2000-03-06 2007-05-22 Surmodics, Inc. Endovascular graft coatings
US9522217B2 (en) 2000-03-15 2016-12-20 Orbusneich Medical, Inc. Medical device with coating for capturing genetically-altered cells and methods for using same
US8088060B2 (en) 2000-03-15 2012-01-03 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US20070141107A1 (en) * 2000-03-15 2007-06-21 Orbusneich Medical, Inc. Progenitor Endothelial Cell Capturing with a Drug Eluting Implantable Medical Device
US20030229393A1 (en) * 2001-03-15 2003-12-11 Kutryk Michael J. B. Medical device with coating that promotes cell adherence and differentiation
CN100506293C (zh) 2000-03-15 2009-07-01 祥丰医疗有限公司 促进内皮细胞粘附的涂层
US8460367B2 (en) * 2000-03-15 2013-06-11 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US20070055367A1 (en) * 2000-03-15 2007-03-08 Orbus Medical Technologies, Inc. Medical device with coating that promotes endothelial cell adherence and differentiation
US20060177416A1 (en) 2003-10-14 2006-08-10 Medivas, Llc Polymer particle delivery compositions and methods of use
US20060013855A1 (en) * 2004-04-05 2006-01-19 Medivas, Llc Bioactive stents for type II diabetics and methods for use thereof
US8163269B2 (en) * 2004-04-05 2012-04-24 Carpenter Kenneth W Bioactive stents for type II diabetics and methods for use thereof
WO2005107817A2 (fr) 2004-04-30 2005-11-17 Orbus Medical Technologies, Inc. Dispositif medical comprenant un revetement permettant de capturer des cellules genetiquement modifiees et ses procedes d'utilisation
MX2007010332A (es) * 2005-02-25 2008-02-21 Univ Utah Res Found Metodos y composiciones para promover adhesion o migracion de celula endotelial.
CA2623198C (fr) 2005-09-22 2014-08-05 Medivas, Llc Formules de poly(ester amide) et de poly(ester urethane) contenant des diesters de bis-(a-amino)-diol et methodes d'emploi
CA2623239C (fr) * 2005-09-22 2016-07-12 Medivas, Llc Compositions polymeres solides pour administration et methodes d'utilisation de celles-ci
EP1962894A4 (fr) * 2005-12-07 2012-11-14 Medivas Llc Procede destine a assembler une composition d'administration polymere-agent biologique
US7807624B2 (en) * 2006-01-11 2010-10-05 Affinergy, Inc. Methods and compositions for promoting attachment of cells of endothelial cell lineage to medical devices
WO2007130477A2 (fr) * 2006-05-02 2007-11-15 Medivas, Llc Administration d'agents ophtalmiques à l'extérieur et à l'intérieur de l'oeil
WO2007133616A2 (fr) * 2006-05-09 2007-11-22 Medivas, Llc Polymères hydrosolubles biodégradables
CA2709412A1 (fr) * 2007-07-24 2009-01-29 Medivas, Llc Compositions polymeres cationiques biodegradables de transfert de gene et procedes d'utilisation
CA2733686A1 (fr) * 2008-08-13 2010-02-18 Medivas, Llc Polymeres biodegradables a base d'aabb-poly(depsipeptides) et procedes d'utilisation
US8808365B2 (en) * 2009-01-07 2014-08-19 Martin Kean Chong Ng Chemically and biologically modified medical devices
US9572693B2 (en) * 2009-05-14 2017-02-21 Orbusneich Medical, Inc. Self-expanding stent with polygon transition zone
KR101922741B1 (ko) * 2011-02-03 2019-02-20 노스이스턴 유니버시티 생물학적 물질의 고도로 특이적인 포획 및 방출을 위한 방법 및 조성물
WO2012175746A1 (fr) 2011-06-23 2012-12-27 Dsm Ip Assets B.V. Nouveaux copolymères biodégradables de polyesteramide destinés à l'administration de médicaments
US9873765B2 (en) 2011-06-23 2018-01-23 Dsm Ip Assets, B.V. Biodegradable polyesteramide copolymers for drug delivery
WO2015148512A1 (fr) 2014-03-24 2015-10-01 Qt Holdings Corp Articles façonnés incluant des hydrogels et leurs procédés de fabrication et d'utilisation
AU2015366355B2 (en) 2014-12-18 2020-05-28 Dsm Ip Assets B.V. Drug delivery system for delivery of acid sensitive drugs
US20160287839A1 (en) * 2015-03-31 2016-10-06 Surefire Medical, Inc. Apparatus and Method for Infusing an Immunotherapy Agent to a Solid Tumor for Treatment
US9790467B2 (en) 2015-09-22 2017-10-17 Qt Holdings Corp Methods and compositions for activation or expansion of T lymphocytes
KR101850779B1 (ko) * 2016-08-12 2018-04-20 서울대학교산학협력단 후기내피전구세포의 포획 및 증식을 위한 hip 스텐트 코팅 조성물 및 이를 이용한 스텐트
CN108852572B (zh) * 2018-07-19 2019-12-06 四川兴泰普乐医疗科技有限公司 一种多层血管支架及其制备方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674722A (en) * 1987-12-11 1997-10-07 Somatix Therapy Corporation Genetic modification of endothelial cells
WO2000002998A1 (fr) * 1998-07-10 2000-01-20 Brigham & Women's Hospital, Inc. Procede d'implantation de cellules
WO2001043696A2 (fr) * 1999-12-16 2001-06-21 Rst Implanted Cell Technology, Llc Methode et dispositif d'implantation
WO2001068158A1 (fr) * 2000-03-15 2001-09-20 Orbus Medical Technologies Inc. Revetement favorisant la fixation des cellules endotheliales
US20020160033A1 (en) * 2001-04-25 2002-10-31 Noel Caplice Implantable medical devices
WO2003065881A2 (fr) * 2002-02-06 2003-08-14 Orbus Medical Technologies Inc. Dispositif medical recouvert d'un revetement qui facilite la fixation et la differenciation de cellules endotheliales

Family Cites Families (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3523807A (en) 1966-11-25 1970-08-11 Mihaly Gerendas Method of making a cross-linked fibrin prosthesis
JPS5313915B2 (fr) 1973-01-25 1978-05-13
US4515160A (en) 1982-04-23 1985-05-07 Medtronic, Inc. Cardiac pacemaker synchronized programming
US4487715A (en) 1982-07-09 1984-12-11 The Regents Of The University Of California Method of conjugating oligopeptides
US4548736A (en) 1983-08-29 1985-10-22 Wisconsin Alumni Research Foundation Preparation of protein films
US4553974A (en) 1984-08-14 1985-11-19 Mayo Foundation Treatment of collagenous tissue with glutaraldehyde and aminodiphosphonate calcification inhibitor
US4962091A (en) 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
US4920016A (en) 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US4795459A (en) 1987-05-18 1989-01-03 Rhode Island Hospital Implantable prosthetic device with lectin linked endothelial cells
US4886062A (en) 1987-10-19 1989-12-12 Medtronic, Inc. Intravascular radially expandable stent and method of implant
EP0366564B1 (fr) 1988-10-28 1995-07-12 Terumo Kabushiki Kaisha Matériau médical antithrombotique, organe interne artificiel et méthode de production d'un matériau médical antithrombotique
US5043165A (en) 1988-12-14 1991-08-27 Liposome Technology, Inc. Novel liposome composition for sustained release of steroidal drugs
US5698531A (en) 1989-03-31 1997-12-16 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5635386A (en) 1989-06-15 1997-06-03 The Regents Of The University Of Michigan Methods for regulating the specific lineages of cells produced in a human hematopoietic cell culture
JPH0366384A (ja) 1989-08-04 1991-03-22 Senjiyu Seiyaku Kk 生理活性物質放出制御システム
US5635482A (en) 1989-08-14 1997-06-03 The Regents Of The University Of California Synthetic compounds and compositions with enhanced cell binding
US5674848A (en) 1989-08-14 1997-10-07 The Regents Of The University Of California Bioreactor compositions with enhanced cell binding
US5059166A (en) 1989-12-11 1991-10-22 Medical Innovative Technologies R & D Limited Partnership Intra-arterial stent with the capability to inhibit intimal hyperplasia
US5199939B1 (en) 1990-02-23 1998-08-18 Michael D Dake Radioactive catheter
JPH05502179A (ja) 1990-02-28 1993-04-22 メドトロニック　インコーポレーテッド 管状器官内薬剤溶出装具
US5545208A (en) 1990-02-28 1996-08-13 Medtronic, Inc. Intralumenal drug eluting prosthesis
AU656544B2 (en) * 1990-10-31 1995-02-09 Brigham And Women's Hospital Genetic modification of endothelial cells
US5198263A (en) 1991-03-15 1993-03-30 The United States Of America As Represented By The United States Department Of Energy High rate chemical vapor deposition of carbon films using fluorinated gases
US5199942A (en) 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
US5302168A (en) 1991-09-05 1994-04-12 Hess Robert L Method and apparatus for restenosis treatment
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5464450A (en) 1991-10-04 1995-11-07 Scimed Lifesystems Inc. Biodegradable drug delivery vascular stent
GB9203037D0 (en) 1992-02-11 1992-03-25 Salutar Inc Contrast agents
US5965132A (en) * 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5310669A (en) 1992-06-22 1994-05-10 The Trustees Of Dartmouth College Fullerene coated surfaces and uses thereof
US5292813A (en) 1992-10-02 1994-03-08 Exxon Research & Engineering Co. Fullerene-grafted polymers and processes of making
WO1994015583A1 (fr) 1993-01-08 1994-07-21 Pdt Systems, Inc. Extenseurs a liberation de medicaments
US5338571A (en) 1993-02-10 1994-08-16 Northwestern University Method of forming self-assembled, mono- and multi-layer fullerene film and coated substrates produced thereby
US5482406A (en) * 1993-04-15 1996-01-09 Continental Emsco Company Variable spring rate compression element and riser tensioner system using the same
US5464650A (en) 1993-04-26 1995-11-07 Medtronic, Inc. Intravascular stent and method
US5641466A (en) 1993-06-03 1997-06-24 Nec Corporation Method of purifying carbon nanotubes
US5558903A (en) 1993-06-10 1996-09-24 The Ohio State University Method for coating fullerene materials for tribology
US6120764A (en) 1993-06-24 2000-09-19 Advec, Inc. Adenoviruses for control of gene expression
US5830760A (en) 1993-07-28 1998-11-03 Fred Hutchinson Cancer Research Center Creating novel hematopoietic cell lines by expressing altered retinoic acid receptors
WO1995005843A1 (fr) 1993-08-25 1995-03-02 Systemix, Inc. Procede de production d'une population de cellules souches hematopoietiques fortement enrichie
CA2187355C (fr) 1994-04-08 2009-10-13 Richard L. Dunn Systeme auxiliaire de polymeres pour dispositif medical
US5536641A (en) 1994-05-17 1996-07-16 Memorial Sloane Kittering Cancer Center Monoclonal antibody specific for vascular endothelial cell antigen endoglyx-1 and uses thereof for detection of, and isolation of, vascular endothelial cells
US5686600A (en) 1994-06-28 1997-11-11 Novartis Finance Corporation Antibodies which bind to insect gut proteins and their use
GB9413029D0 (en) 1994-06-29 1994-08-17 Common Services Agency Stem cell immobilisation
US6249703B1 (en) 1994-07-08 2001-06-19 Medtronic, Inc. Handheld patient programmer for implantable human tissue stimulator
EP0698396B1 (fr) 1994-08-12 2001-12-12 Meadox Medicals, Inc. Greffe vasculaire imprégnée d'un matériau d'étanchéité contenant de l'héparine et du collagène
US6281015B1 (en) 1994-12-16 2001-08-28 Children's Medical Center Corp. Localized delivery of factors enhancing survival of transplanted cells
US6231600B1 (en) 1995-02-22 2001-05-15 Scimed Life Systems, Inc. Stents with hybrid coating for medical devices
CA2216919C (fr) 1995-03-28 2007-09-18 Fidia Advanced Biopolymers Srl Nanospheres contenant un polysaccharidique biocompatible
US5661127A (en) 1995-05-01 1997-08-26 The Regents Of The University Of California Peptide compositions with growth factor-like activity
US5780436A (en) 1995-05-01 1998-07-14 The Regents Of The University Of California Peptide compositions with growth factor-like activity
US5603722A (en) 1995-06-06 1997-02-18 Quanam Medical Corporation Intravascular stent
US5865723A (en) 1995-12-29 1999-02-02 Ramus Medical Technologies Method and apparatus for forming vascular prostheses
US6033582A (en) 1996-01-22 2000-03-07 Etex Corporation Surface modification of medical implants
WO1997029802A2 (fr) 1996-02-20 1997-08-21 Advanced Bionics Corporation Microstimulateur implantable ameliore et systemes d'utilisation associes
CA2247820C (fr) 1996-03-06 2009-02-24 Hyperion Catalysis International, Inc. Nanotubes fonctionnalises
GB9606188D0 (en) 1996-03-23 1996-05-29 Danbiosyst Uk Pollysaccharide microspheres for the pulmonary delivery of drugs
GB9606452D0 (en) 1996-03-27 1996-06-05 Sandoz Ltd Organic compounds
US5843633A (en) 1996-04-26 1998-12-01 Amcell Corporation Characterization of a human hematopoietic progenitor cell antigen
US6455678B1 (en) 1996-04-26 2002-09-24 Amcell Corporation Human hematopoietic stem and progenitor cell antigen
WO1998015317A1 (fr) 1996-10-07 1998-04-16 Sulzer Intermedics Inc. Electrode a injection de medicament regulable
CA2270154A1 (fr) 1996-10-25 1998-04-30 The Government Of The United States Of America As Represented By The Sec Retary, Department Of Health And Human Services Procede et compositions pour inhiber des inflammations et des angiogeneses comprenant une sous-unite de cd97 alpha de mammiferes
US6500421B1 (en) 1996-11-04 2002-12-31 St. Jude Children's Research Hospital In vivo selection of primitive hematopoietic cells
AU5173598A (en) 1996-11-08 1998-06-10 Ikonos Corporation Method for coating substrates
US5980887A (en) 1996-11-08 1999-11-09 St. Elizabeth's Medical Center Of Boston Methods for enhancing angiogenesis with endothelial progenitor cells
US5753088A (en) 1997-02-18 1998-05-19 General Motors Corporation Method for making carbon nanotubes
US6258939B1 (en) 1997-03-10 2001-07-10 The Regents Of The University Of California PSCA antibodies and hybridomas producing them
US6273913B1 (en) 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
EP0884029B1 (fr) 1997-06-13 2004-12-22 Gary J. Becker Endoprothèse intraluminale extensible
US6077987A (en) 1997-09-04 2000-06-20 North Shore-Long Island Jewish Research Institute Genetic engineering of cells to enhance healing and tissue regeneration
US6440734B1 (en) 1998-09-25 2002-08-27 Cytomatrix, Llc Methods and devices for the long-term culture of hematopoietic progenitor cells
US5945457A (en) 1997-10-01 1999-08-31 A.V. Topchiev Institute Of Petrochemical Synthesis, Russian Academy Of Science Process for preparing biologically compatible polymers and their use in medical devices
US5980565A (en) 1997-10-20 1999-11-09 Iowa-India Investments Company Limited Sandwich stent
AU761758B2 (en) 1997-11-14 2003-06-12 Cedars-Sinai Medical Center Transfection and transfer of male germ cells for generation of transgenic species
US20020053092A1 (en) 1997-11-14 2002-05-02 Readhead Carol W. Nucleic acid constructs containing a cyclin A1 promoter, and kit
US6197586B1 (en) 1997-12-12 2001-03-06 The Regents Of The University Of California Chondrocyte-like cells useful for tissue engineering and methods
EP1039944B1 (fr) 1997-12-19 2008-02-20 Cordis Corporation Systeme de catheter avec fullerenes
WO1999035245A2 (fr) 1998-01-12 1999-07-15 Board Of Regents, The University Of Texas System Procedes pour preparer et utiliser des cellules neuroendocriniennes humaines immortalisees
US20020051762A1 (en) 1998-01-23 2002-05-02 Shahin Rafii Purified populations of endothelial progenitor cells
US6541116B2 (en) 1998-01-30 2003-04-01 Advanced Cardiovascular Systems, Inc. Superoxide dismutase or superoxide dismutase mimic coating for an intracorporeal medical device
US20030125615A1 (en) 1998-02-05 2003-07-03 Yitzhack Schwartz Homing of autologous cells to a target zone in tissue using active therapeutics or substances
US6140127A (en) 1998-02-18 2000-10-31 Cordis Corporation Method of coating an intravascular stent with an endothelial cell adhesive five amino acid peptide
US6676937B1 (en) * 1998-03-09 2004-01-13 Caritas St. Elizabeth's Medical Center Of Boston Inc. Compositions and methods for modulating vascularization
AU766238B2 (en) * 1998-03-09 2003-10-09 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Compositions and methods for modulating vascularization
US6482406B1 (en) 1999-03-26 2002-11-19 Duncan J. Stewart Cell-based gene therapy for the pulmonary system
BR9909717A (pt) 1998-04-17 2000-12-26 Angiogenix Inc Fatores angiogênicos terapêuticos e métodos para seu uso
DE69915235T2 (de) 1998-04-30 2005-04-14 Medtronic, Inc., Minneapolis Implantierbares system, das medikamente freisetzende zellen enthält, für eine bedarfsgerechte, lokale verabreichung von medikamenten
US6206914B1 (en) 1998-04-30 2001-03-27 Medtronic, Inc. Implantable system with drug-eluting cells for on-demand local drug delivery
US6153252A (en) 1998-06-30 2000-11-28 Ethicon, Inc. Process for coating stents
US6342344B1 (en) 1998-07-31 2002-01-29 Stemcell Technologies Inc. Antibody composition for isolating human cells from human-murine chimeric hematopoietic cell suspensions
JP2000086699A (ja) 1998-09-07 2000-03-28 Seikagaku Kogyo Co Ltd 細胞表面抗原ｃｄ１４を認識する新規なモノクローナル抗体
US6375680B1 (en) 1998-12-01 2002-04-23 St. Jude Medical, Inc. Substrates for forming synthetic tissues
EP1020166A1 (fr) 1999-01-12 2000-07-19 Orbus Medical Technologies, Inc. Endoprothèse intraluminale expansible
JP2002534210A (ja) 1999-01-14 2002-10-15 アドバンスド ティシュー サイエンシズ，インコーポレーテッド 組織、人造又は天然脈管移植片の滅菌、接種、培養、保存、輸送および試験のための装置および方法
DE19903385A1 (de) 1999-01-29 2000-08-03 Max Delbrueck Centrum Mittel zur Prävention von In-Stent Restenosen und postoperativen Entzündungen
US6258121B1 (en) 1999-07-02 2001-07-10 Scimed Life Systems, Inc. Stent coating
AU778386B2 (en) 1999-07-28 2004-12-02 Board Of Trustees Of The Leland Stanford Junior University Nicotine receptor agonists in stem cell and progenitor cell recruitment
US6371980B1 (en) 1999-08-30 2002-04-16 Cardiovasc, Inc. Composite expandable device with impervious polymeric covering and bioactive coating thereon, delivery apparatus and method
US6159531A (en) 1999-08-30 2000-12-12 Cardiovasc, Inc. Coating having biological activity and medical implant having surface carrying the same and method
AU2001245550A1 (en) 2000-03-09 2001-09-17 Lee Walters Applications of immune system tolerance to treatment of various diseases
US9522217B2 (en) 2000-03-15 2016-12-20 Orbusneich Medical, Inc. Medical device with coating for capturing genetically-altered cells and methods for using same
US20030229393A1 (en) 2001-03-15 2003-12-11 Kutryk Michael J. B. Medical device with coating that promotes cell adherence and differentiation
US20050271701A1 (en) 2000-03-15 2005-12-08 Orbus Medical Technologies, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
WO2001094420A1 (fr) 2000-06-05 2001-12-13 The Trustees Of Columbia University In The City Of New York Identification et utilisation des cellules progenitrices endotheliales derivees de la moelle osseuse, destinees a ameliorer la fonction du myocarde apres un accident ischemique
US7175658B1 (en) * 2000-07-20 2007-02-13 Multi-Gene Vascular Systems Ltd. Artificial vascular grafts, their construction and use
HUP0300810A2 (hu) 2000-07-20 2003-08-28 M.G.V.S. Ltd. Mesterséges értranszplantátum, valamint ennek létrehozása és alkalmazása
IL137860A0 (en) 2000-08-15 2001-10-31 Baruch David Coronary membrane covered stent
US6607720B1 (en) 2000-09-05 2003-08-19 Yong-Fu Xiao Genetically altered mammalian embryonic stem cells, their living progeny, and their therapeutic application for improving cardiac function after myocardial infarction
US6548025B1 (en) 2000-11-08 2003-04-15 Illinois Institute Of Technology Apparatus for generating odor upon electronic signal demand
US6471980B2 (en) 2000-12-22 2002-10-29 Avantec Vascular Corporation Intravascular delivery of mycophenolic acid
WO2002057436A2 (fr) 2001-01-19 2002-07-25 Gendel Limited Administration d'un polypeptide
WO2002060416A1 (fr) 2001-02-01 2002-08-08 Gendel Limited Systeme d'administration de polypeptide et leur procede de preparation
US20040234972A1 (en) 2001-03-20 2004-11-25 Owens Gary K. Method for identifying and purifying smooth muscle progenitor cells
US6613083B2 (en) 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
WO2002089727A2 (fr) 2001-05-03 2002-11-14 The John Hopkins University Methodes d'utilisation de la cytokine c17
US7666393B2 (en) 2001-05-11 2010-02-23 Children's Medical Center Corporation Methods for assessing antiangiogenic agents
FI20011132A0 (fi) 2001-05-30 2001-05-30 Innovationsagentur Markkeri hematopoieettisten kantasolujen tunnistamiseen
CA2452707A1 (fr) 2001-05-31 2002-12-05 Enteromed Inc. Traitement ou therapie de remplacement faisant appel a des cellules souches transgeniques introduites dans l'intestin
ES2181593B2 (es) 2001-06-14 2004-04-16 Universidad Complutense De Madrid Metodo para la obtencion de implantes bioactivos utiles como sistemas de liberacion controlada de antibioticos.
US20030147859A1 (en) 2001-06-18 2003-08-07 Yair Reisner Methods of utilizing cultured hematopoietic progenitor cells for inducing immunological tolerance
JP4773638B2 (ja) 2001-06-28 2011-09-14 株式会社ジャパーナ ゴルフシューズ用スパイク鋲
JP4332832B2 (ja) * 2001-07-06 2009-09-16 富士電機デバイステクノロジー株式会社 垂直磁気記録媒体およびその製造方法
DE10136324B4 (de) 2001-07-26 2004-01-29 Robert Bosch Gmbh Anordnung mit einem Steuergerät und einem Zustandserfassungsgerät sowie Verfahren zu Prüfung/Diagnose einer solchen Anordnung
WO2003019136A2 (fr) 2001-08-06 2003-03-06 The Regents Of The University Of California Procedes d'inhibition d'angiogenese
AU2002359340A1 (en) 2001-10-31 2003-05-12 Ventrigraft Inc Methods and device compositions for the recruitment of cells to blood contacting surfaces in vivo
DE10160110A1 (de) 2001-12-07 2003-06-26 Norbert Hoenzelaer Vorrichtung und Pflaster zur kontrollierten Freisetzung von Vanillin
WO2003063575A2 (fr) 2002-01-29 2003-08-07 Colb A Mark Endothelisation de surfaces vasculaires
US20030181973A1 (en) 2002-03-20 2003-09-25 Harvinder Sahota Reduced restenosis drug containing stents
EP1497410A4 (fr) 2002-04-01 2005-05-25 Peter K Law Transplantation cellulaire pour regeneration cardiaque
JP4136434B2 (ja) 2002-04-17 2008-08-20 進 清野 インスリン産生細胞の誘導
CN1655738A (zh) 2002-05-20 2005-08-17 奥勃斯医学技术股份有限公司 可植入的药物洗脱医疗装置
EP1410812A1 (fr) 2002-10-14 2004-04-21 EC (European Community) Fonctionnalisation de protheses endovasculaires avec des lipases
US20040220656A1 (en) 2003-04-30 2004-11-04 Epstein Samuel J. Coated medical devices and methods of making the same
US20050149174A1 (en) 2003-12-18 2005-07-07 Medtronic Vascular, Inc. Medical devices to treat or inhibit restenosis
US20050187607A1 (en) 2004-02-20 2005-08-25 Akhtar Adil J. Drug delivery device
WO2005107817A2 (fr) 2004-04-30 2005-11-17 Orbus Medical Technologies, Inc. Dispositif medical comprenant un revetement permettant de capturer des cellules genetiquement modifiees et ses procedes d'utilisation

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674722A (en) * 1987-12-11 1997-10-07 Somatix Therapy Corporation Genetic modification of endothelial cells
WO2000002998A1 (fr) * 1998-07-10 2000-01-20 Brigham & Women's Hospital, Inc. Procede d'implantation de cellules
WO2001043696A2 (fr) * 1999-12-16 2001-06-21 Rst Implanted Cell Technology, Llc Methode et dispositif d'implantation
WO2001068158A1 (fr) * 2000-03-15 2001-09-20 Orbus Medical Technologies Inc. Revetement favorisant la fixation des cellules endotheliales
US20020160033A1 (en) * 2001-04-25 2002-10-31 Noel Caplice Implantable medical devices
WO2003065881A2 (fr) * 2002-02-06 2003-08-14 Orbus Medical Technologies Inc. Dispositif medical recouvert d'un revetement qui facilite la fixation et la differenciation de cellules endotheliales

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
CARDIOVASCULAR RESEARCH, vol. 61, no. 1, 1 January 2004 (2004-01-01), pages 177 - 185, ISSN: 0008-6363 *
CIRCULATION, vol. 101, no. 8, 29 February 2000 (2000-02-29), pages 923 - 930, ISSN: 0009-7322 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1 January 2004 (2004-01-01), NUMAGUCHI YASUSHI ET AL: "Catheter-based prostacyclin synthase gene transfer prevents in-stent restenosis in rabbit atheromatous arteries.", XP002507939, Database accession no. PREV200400208546 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1994, SUN B ET AL: "In vitro expression of calcitonin gene-related peptide in human endothelial cells transfected with plasmid and retroviral vectors", XP002507940, Database accession no. PREV199497223480 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 29 February 2000 (2000-02-29), CHAMPION HUNTER C ET AL: "In vivo gene transfer of prepro-calcitonin gene-related peptide to the lung attenuates chronic hypoxia-induced pulmonary hypertension in the mouse", XP002507941, Database accession no. PREV200000227003 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; March 2003 (2003-03-01), CHATTERGOON NATASHA N ET AL: "Role of eNOS, CGRP and p53 in vascular smooth muscle cell proliferation.", XP002507942, Database accession no. PREV200300391695 *
FASEB JOURNAL, vol. 17, no. 4-5, March 2003 (2003-03-01), FASEB MEETING ON EXPERIMENTAL BIOLOGY: TRANSLATING THE GENOME; SAN DIEGO, CA, USA; APRIL 11-15, 2003, pages Abstract No. 564.3 URL - http://ww, ISSN: 0892-6638 *
NEUROPEPTIDES, vol. 26, no. 3, 1994, pages 167 - 173, ISSN: 0143-4179 *

Also Published As

Publication number Publication date
KR20070008714A (ko) 2007-01-17
EP1740219B1 (fr) 2015-03-04
EP1740219A2 (fr) 2007-01-10
EP2946666B1 (fr) 2017-11-15
US20060121012A1 (en) 2006-06-08
CA2563329C (fr) 2016-01-26
US9364565B2 (en) 2016-06-14
WO2005107817A3 (fr) 2007-08-23
TW200605910A (en) 2006-02-16
WO2005107817A2 (fr) 2005-11-17
CA2563329A1 (fr) 2005-11-17
EP2946666A1 (fr) 2015-11-25
JP2007535389A (ja) 2007-12-06

Similar Documents

Publication Publication Date Title
EP1740219A4 (fr) Dispositif medical comprenant un revetement permettant de capturer des cellules genetiquement modifiees et ses procedes d'utilisation
EP1743365A4 (fr) Dispositif de saisie de sonde pour cystotomie et méthode d"utilisation
EP1866408A4 (fr) Dispositif electronique de manipulation de cellules et procede associe
EP2091588A4 (fr) Dispositif cardiaque et ses procédés d'utilisation
EP2028997A4 (fr) Dispositif de communication et procédé utilisant le corps humain
EP2111170A4 (fr) Dispositif et procédés de retenue d'implant
EP1976452A4 (fr) Dispositif médical souple et son procédé d'utilisation
EP2073752A4 (fr) Dispositifs implantables pour le traitement de l'incontinence, et leurs procédés d'utilisation
EP1802244A4 (fr) Dispositifs et procedes d'ablation avec imagerie par ultrasons
GB2453676B (en) Lumen-traveling biological interface device and method of use
GB2423933B (en) Medical apparatus and method of use thereof
EP1804843A4 (fr) Structure de suture adhesive et leurs procedes d'utilisation
EP2237735A4 (fr) Dispositif de fixation intermaxillaire et procédé d'utilisation correspondant
EP2175792A4 (fr) Dispositif de traitement cutané ou corporel multimodule et procédé d'utilisation
EP1909644A4 (fr) Appareil d'insertion et procédés d'utilisation
GB0403335D0 (en) Medical injector handling device
EP2061377A4 (fr) Dispositif d'extraction de tissu et son procédé d'utilisation
EP1896122A4 (fr) Dispositif et procede de traitement de tissu
EP1763490A4 (fr) Appareil d'électrodéionisation et méthodes d'utilisation
PL2625953T3 (pl) Udojowe urządzenie i sposób jego użycia
EP2081644A4 (fr) Dispositif et procédé de stimulation de tissu
IL165614A0 (en) Analog metamonitoring device and method
TWI350207B (en) Coating device and coating method
EP1788409A4 (fr) Dispositif d'magerie radiologique et procédé d'magerie radiologique
GB0427930D0 (en) Implant device and method

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060824

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR LV MK YU

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1098968

Country of ref document: HK

DAX Request for extension of the european patent (deleted)
PUAK Availability of information related to the publication of the international search report

Free format text: ORIGINAL CODE: 0009015

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/395 20060101ALI20070910BHEP

Ipc: C12N 5/02 20060101ALI20070910BHEP

Ipc: C12N 5/00 20060101ALI20070910BHEP

Ipc: C12N 15/00 20060101ALI20070910BHEP

Ipc: A61K 31/70 20060101ALI20070910BHEP

Ipc: A01N 65/00 20060101ALI20070910BHEP

Ipc: A01N 63/00 20060101ALI20070910BHEP

Ipc: A01N 43/00 20060101AFI20070910BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20090105

17Q First examination report despatched

Effective date: 20090407

APBK Appeal reference recorded

Free format text: ORIGINAL CODE: EPIDOSNREFNE

APBN Date of receipt of notice of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA2E

APBR Date of receipt of statement of grounds of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA3E

APBV Interlocutory revision of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNIRAPE

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1098968

Country of ref document: HK

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Ref document number: 602005045964

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: A61K0048000000

Ipc: A01N0043000000

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/70 20060101ALI20140919BHEP

Ipc: C12N 15/00 20060101ALI20140919BHEP

Ipc: C12N 5/00 20060101ALI20140919BHEP

Ipc: A01N 43/00 20060101AFI20140919BHEP

Ipc: A01N 65/00 20090101ALI20140919BHEP

Ipc: A61K 48/00 20060101ALI20140919BHEP

Ipc: A01N 63/00 20060101ALI20140919BHEP

Ipc: C12N 5/02 20060101ALI20140919BHEP

INTG Intention to grant announced

Effective date: 20141014

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602005045964

Country of ref document: DE

Effective date: 20150409

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 712972

Country of ref document: AT

Kind code of ref document: T

Effective date: 20150415

REG Reference to a national code

Ref country code: NL

Ref legal event code: T3

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 712972

Country of ref document: AT

Kind code of ref document: T

Effective date: 20150304

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150304

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150304

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150304

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150304

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150304

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150605

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150706

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150304

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150304

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150304

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150304

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150704

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150304

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150304

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602005045964

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150304

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150304

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150430

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150430

26N No opposition filed

Effective date: 20151207

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150304

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 12

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 13

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20050429

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150304

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150304

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150304

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150429

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 14

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 602005045964

Country of ref document: DE

Representative=s name: DEHNS PATENT AND TRADEMARK ATTORNEYS, DE

Ref country code: DE

Ref legal event code: R082

Ref document number: 602005045964

Country of ref document: DE

Representative=s name: DEHNS PATENT AND TRADE MARK ATTORNEYS, DE

Ref country code: DE

Ref legal event code: R081

Ref document number: 602005045964

Country of ref document: DE

Owner name: ORBUSNEICH MEDICAL PTE. LTD., SG

Free format text: FORMER OWNER: ORBUSNEICH MEDICAL, INC., FORT LAUDERDALE, FLA., US

REG Reference to a national code

Ref country code: BE

Ref legal event code: FP

Effective date: 20150604

Ref country code: BE

Ref legal event code: PD

Owner name: ORBUSNEICH MEDICAL PTE. LTD; SG

Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), CESSION; FORMER OWNER NAME: ORBUSNEICH MEDICAL, INC.

Effective date: 20190208

REG Reference to a national code

Ref country code: NL

Ref legal event code: PD

Owner name: ORBUSNEICH MEDICAL PTE. LTD; SG

Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), ASSIGNMENT; FORMER OWNER NAME: ORBUSNEICH MEDICAL, INC.

Effective date: 20190304

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

Free format text: REGISTERED BETWEEN 20190523 AND 20190529

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20190429

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20190418

Year of fee payment: 15

Ref country code: IE

Payment date: 20190418

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20190418

Year of fee payment: 15

Ref country code: BE

Payment date: 20190429

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20190416

Year of fee payment: 15

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602005045964

Country of ref document: DE

REG Reference to a national code

Ref country code: NL

Ref legal event code: MM

Effective date: 20200501

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200430

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201103

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20200430

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200430

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20200429

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200501

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200429

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200429